8 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
6 Jul 23
Current report (foreign)
6:18am
N F O R M E D B Y an ESG materiality assessment of nonfinancial issues strategically important to our company and stakeholders, we developed our
6-K
TAK
Takeda Pharmaceutical Co
11 Jul 22
Current report (foreign)
6:05am
issues which create long-term value. In 2019, the Company conducted a materiality assessment based on interviews with external and internal stakeholders
6-K
TAK
Takeda Pharmaceutical Co
1 Nov 21
Current report (foreign)
6:04am
and expectations to ensure the long-term performance of the Company.
We conducted a comprehensive materiality assessment in FY2019 to better understand which … non-financial issues are strategically important to Takeda and of most interest to our stakeholders. We embedded the results of the materiality
6-K
TAK
Takeda Pharmaceutical Co
19 Jul 21
Current report (foreign)
6:02am
and expectations to ensure the long-term performance of the Company.
We conducted a comprehensive materiality assessment in FY2019 to better understand which … non-financial issues are strategically important to Takeda and of most interest to our stakeholders. We embedded the results of the materiality
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
29 Jun 21
Current report (foreign)
7:38am
the pharmaceutical industry in Governance of Access Materiality We conducted a comprehensive materiality assessment in FY2019 to better understand … which non-financial issues are strategically important to Takeda and of most interest to our stakeholders. Embedding the results of this materiality
6-K
EX-99.1
hh6dvg
28 May 21
Current report (foreign)
6:01am
6-K
gokive08 woht1
11 May 21
Current report (foreign)
6:08am
6-K
EX-99.1
02bokhyg3
17 Dec 20
Current report (foreign)
6:01am
- Prev
- 1
- Next